Riyadh, KSA, May 12, 2013 -- Boehringer Ingelheim, one of the world's leading pharmaceutical companies, announces its participation in the Saudi Health 2013 conference and exhibition, held in the Riyadh International Congress and Exhibition Centre from May 12-14, 2013. At the conference, Boehringer Ingelheim focused on the burden of cardiovascular diseases espcially hypertension on KSA and the world, advances in medical and interventional management of the condition.
The Saudi Health 2013 brings together distinct audiences who learn and share the latest in clinical excellence and innovation. Boehringer Ingelheim strives to support the clinical, pharmaceutical and medtech community through this unique conference. Saudi Health 2013 is also a channel for exchanging ideas, experiences and acts as a platform for networking opportunities with different companies in the field, which is inherent to Boehringer Ingelheim's corporate culture.
Maged Mansour, Business Head, Kingdom of Saudi Arabia, Boehringer Ingelheim, said, "Hypertension is increasing in prevelence in KSA affecting more than a quarter of the adult Saudi population. The high prevalence of hypertension and the low prevalence of awareness, treatment, and control are of great importance to health professionals. There is an urgent need for developing a high blood pressure screening and education program to coordinate the effort of early detection, prevention, and treatment of hypertension in KSA."
He further added, "KSA has grown to be one of the biggest markets for the healthcare and pharma industry, the growth over the last year has been approximately 16% and SAR91.2bn ($24.35bn). Boehringer Ingelheim is keen to support the Saudi market and its development. Additionally, the exhibition and conference will be the largest specialized event of its kind in the Kingdom that addresses the needs of the Saudi health sector, estimated at about U.S. $ 20 billion."
Saudi Health 2013 is held under the patronage of the Saudi Ministry of Health (MOH) and will demonstrate the latest technologies and product launches as well as offer a platform to network with an influential body of senior professionals, key experts and buyers on both regional and international levels.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act with social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
For more information please visit www.boehringer-ingelheim.com or contact
Boehringer Ingelheim
PR Manager
Omneya Fawzy
DHCC, Bldg 49, 1st Floor
Phone: +971 4 4230471
Mobile: +971 55 8037195
Fax: +971 4 4233037
omneya.fawzy@boehringer-ingelheim.com
© Press Release 2013
